Cargando…
Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19), which poses a major threat to humans worldwide. With the continuous progress of the pandemic, a growing number of people are infected with SARS-CoV-2, including hepatocellular carcinoma (...
Autores principales: | Wang, Luhong, Ding, Yinan, Zhang, Chuanyong, Chen, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154116/ https://www.ncbi.nlm.nih.gov/pubmed/35639708 http://dx.doi.org/10.1371/journal.pone.0269249 |
Ejemplares similares
-
Pharmacological therapies and drug development targeting SARS-CoV-2 infection
por: Jiang, Yizhou, et al.
Publicado: (2022) -
In silico prediction of mozenavir as a potential drug for SARS-CoV-2 infection via binding multiple drug targets
por: Mamidala, Estari, et al.
Publicado: (2022) -
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma
por: Guarino, Maria, et al.
Publicado: (2022) -
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021) -
The SARS-CoV-2 main protease as drug target
por: Ullrich, Sven, et al.
Publicado: (2020)